MY106315A - Pharmaceutical agents - Google Patents

Pharmaceutical agents

Info

Publication number
MY106315A
MY106315A MYPI91002302A MYPI19912302A MY106315A MY 106315 A MY106315 A MY 106315A MY PI91002302 A MYPI91002302 A MY PI91002302A MY PI19912302 A MYPI19912302 A MY PI19912302A MY 106315 A MY106315 A MY 106315A
Authority
MY
Malaysia
Prior art keywords
physical form
methyl
methylindol
methoxybenzoyl
amino
Prior art date
Application number
MYPI91002302A
Other languages
English (en)
Inventor
Clements Arlene
John Bradway Randy
John Edwards Ieuan
Joseph Timko Robert
Joseph Holohan James
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY106315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of MY106315A publication Critical patent/MY106315A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI91002302A 1990-12-12 1991-12-11 Pharmaceutical agents MY106315A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Publications (1)

Publication Number Publication Date
MY106315A true MY106315A (en) 1995-04-29

Family

ID=26298105

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI91002302A MY106315A (en) 1990-12-12 1991-12-11 Pharmaceutical agents

Country Status (30)

Country Link
US (6) US5319097A (cg-RX-API-DMAC7.html)
EP (1) EP0490648B1 (cg-RX-API-DMAC7.html)
JP (1) JP2585495B2 (cg-RX-API-DMAC7.html)
KR (2) KR0183027B1 (cg-RX-API-DMAC7.html)
CN (2) CN1043405C (cg-RX-API-DMAC7.html)
AP (1) AP285A (cg-RX-API-DMAC7.html)
AT (1) ATE131048T1 (cg-RX-API-DMAC7.html)
AU (1) AU656157B2 (cg-RX-API-DMAC7.html)
BE (1) BE1004229A5 (cg-RX-API-DMAC7.html)
CA (2) CA2319308C (cg-RX-API-DMAC7.html)
CZ (1) CZ283181B6 (cg-RX-API-DMAC7.html)
DE (2) DE4140858A1 (cg-RX-API-DMAC7.html)
DK (1) DK0490648T3 (cg-RX-API-DMAC7.html)
ES (1) ES2079589T3 (cg-RX-API-DMAC7.html)
FI (1) FI101193B1 (cg-RX-API-DMAC7.html)
FR (1) FR2670488B1 (cg-RX-API-DMAC7.html)
GB (2) GB2251791B (cg-RX-API-DMAC7.html)
GR (1) GR3018318T3 (cg-RX-API-DMAC7.html)
HK (2) HK81597A (cg-RX-API-DMAC7.html)
HU (2) HU213211B (cg-RX-API-DMAC7.html)
IE (1) IE75348B1 (cg-RX-API-DMAC7.html)
IL (1) IL100091A (cg-RX-API-DMAC7.html)
IT (1) IT1256282B (cg-RX-API-DMAC7.html)
MX (1) MX9102473A (cg-RX-API-DMAC7.html)
MY (1) MY106315A (cg-RX-API-DMAC7.html)
NZ (1) NZ240939A (cg-RX-API-DMAC7.html)
PH (1) PH30928A (cg-RX-API-DMAC7.html)
RU (1) RU2106140C1 (cg-RX-API-DMAC7.html)
SK (2) SK279813B6 (cg-RX-API-DMAC7.html)
TW (1) TW276181B (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (cg-RX-API-DMAC7.html) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) * 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (cg-RX-API-DMAC7.html) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
WO2001021211A2 (en) * 1999-09-20 2001-03-29 Alza Corporation Process for lessening polymorphic conversion of a drug
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MEP27808A (en) * 2001-01-26 2010-10-10 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
PT1355644E (pt) 2001-01-26 2006-11-30 Schering Corp Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
CA2453182A1 (en) * 2001-07-10 2003-01-23 Meredith L. Greene Crystalline thiazine oxazolidinones
US20030069298A1 (en) * 2001-08-15 2003-04-10 Pharmacia & Upjohn Company Crystals including a malic acid salt of a 3-pyrrole substituted 2-indolinone, and compositions thereof
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2004081003A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
WO2004081002A1 (en) * 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090191183A1 (en) * 2007-07-30 2009-07-30 Auspex Pharmaceuticals, Inc. Substituted indoles
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
EP3096760A1 (en) 2014-01-22 2016-11-30 Takeda GmbH Treatment of partly controlled or uncontrolled severe asthma with a pde4 inhibitor (and in combination with a leukotriene modifier)
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
BR112019015721A2 (pt) 2017-01-30 2020-03-24 Western New England University Inibidores de tiol isomerases e uso dos mesmos
US10752585B2 (en) 2017-12-28 2020-08-25 Council Of Scientific & Industrial Research Process for the preparation of Zafirlukast and analogs thereof
CA3219671A1 (en) 2021-05-19 2022-11-24 Thomas Christian Lines Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
WO2023214391A1 (en) 2022-05-06 2023-11-09 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds

Also Published As

Publication number Publication date
AU8899491A (en) 1992-06-18
CN1043405C (zh) 1999-05-19
IT1256282B (it) 1995-11-29
DE4140858A1 (de) 1992-06-17
GB9418154D0 (en) 1994-10-26
DE69115229T2 (de) 1996-05-09
SK279813B6 (sk) 1999-04-13
RU2106140C1 (ru) 1998-03-10
EP0490648B1 (en) 1995-12-06
GB2251791B (en) 1995-05-17
HK81397A (en) 1997-06-27
AU656157B2 (en) 1995-01-27
US5504216A (en) 1996-04-02
FI101193B (fi) 1998-05-15
CZ283181B6 (cs) 1998-01-14
CA2056066C (en) 2002-04-02
US6143775A (en) 2000-11-07
HU211126A9 (en) 1995-10-30
KR0183027B1 (ko) 1999-05-01
PH30928A (en) 1997-12-23
KR920011493A (ko) 1992-07-24
DE69115229D1 (de) 1996-01-18
SK279814B6 (sk) 1999-04-13
JP2585495B2 (ja) 1997-02-26
GB2280606B (en) 1995-05-17
AP285A (en) 1993-09-23
BE1004229A5 (fr) 1992-10-13
FI915826A0 (fi) 1991-12-11
US5319097A (en) 1994-06-07
FI101193B1 (fi) 1998-05-15
US5993859A (en) 1999-11-30
EP0490648A1 (en) 1992-06-17
ATE131048T1 (de) 1995-12-15
CS375691A3 (en) 1992-06-17
KR970005014A (ko) 1997-01-29
CA2319308A1 (en) 1992-06-13
GB9126354D0 (en) 1992-02-12
IE914310A1 (en) 1992-06-17
HK81597A (en) 1997-06-27
GB2251791A (en) 1992-07-22
CN1243827A (zh) 2000-02-09
HUT61281A (en) 1992-12-28
GB2280606A (en) 1995-02-08
ES2079589T3 (es) 1996-01-16
JPH04266824A (ja) 1992-09-22
AP9100340A0 (en) 1992-01-31
FI915826L (fi) 1992-03-31
NZ240939A (en) 1994-05-26
IL100091A0 (en) 1992-08-18
HU213211B (en) 1997-03-28
CN1105705C (zh) 2003-04-16
IE75348B1 (en) 1997-08-27
FR2670488A1 (fr) 1992-06-19
DK0490648T3 (da) 1996-05-06
CA2319308C (en) 2001-08-21
ITMI913324A0 (it) 1991-12-11
TW276181B (cg-RX-API-DMAC7.html) 1996-05-21
CN1062291A (zh) 1992-07-01
HU913865D0 (en) 1992-02-28
IL100091A (en) 1998-08-16
KR100207802B1 (ko) 1999-07-15
FR2670488B1 (fr) 1994-01-28
US5612367A (en) 1997-03-18
MX9102473A (es) 1992-06-01
CA2056066A1 (en) 1992-06-13
GR3018318T3 (en) 1996-03-31
ITMI913324A1 (it) 1993-06-11
US5482963A (en) 1996-01-09

Similar Documents

Publication Publication Date Title
MY106315A (en) Pharmaceutical agents
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
NO960067L (no) Nytt farmasöytisk preparat
MX9702380A (es) Nuevas carboxamidas con actividad antifungica.
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
HUP9603237A2 (hu) (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihidro-benzizotiazol-2-il)-butil]-amino-metil}-kromán kristályos hidrokloridja, eljárás előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
MX9706647A (es) Composiciones farmaceuticas que comprenden inhibidores de oxidasa b de monoamina.
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
BG105256A (en) Muscarinic agonists and antagonists
IL84844A0 (en) Pharmaceutical compositions comprising a certain carbazolone derivative or a salt thereof
NZ240481A (en) Aminosulphonyl urea derivatives and pharmaceutical compositions
NO306400B1 (no) N-substituerte azabicykloheptan-derivater, anvendelse derav og farmasöytisk preparat
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
BG105204A (en) Salts of paroxetine
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
EP0373771A3 (en) New pharmaceutical uses for cystatins
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it
PL323305A1 (en) Applications of allyl amines
NO972450L (no) Substituerte 2-(fosfinyloksymetyl)-1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metode for anvendelse derav
HUP0000812A2 (hu) Myelin bázikus fehérje peptid-fragmentumai az azokat tartalmazó gyógyszerkészítmények és felhasználásuk a sclerosis multiplex kezelésére